Clinicians face challenging questions about the evolution and clinical implementation of recently updated cholesterol lowering guidelines and the apparent abandonment of LDL-C goals for treatment. Dr. Evan A Stein MD, PhD, Director Emeritus, Metabolic & Atherosclerosis Research Center in Cincinnati, responds to questions regarding updated cholesterol lowering guidelines, the relationship between LDL-C and CVD risk reduction, the unmet need for additional LDL-C lowering medications and the potential for PCSK9 monoclonal antibodies to address the greatest unmet need -- patients unable to tolerate statins or effective doses of statins and patients with more severe elevations of LDL-C.
Intolerance to statins is seen frequently by primary care physicians in clinical practice. Most common adverse events reported by the patients are muscle weakness and increased hepatic enzymes. These side effects of statin therapy lead to reduced adherence and, ultimately, reduced cardiovascular benefit. This activity discusses the lifestyle, diet, and pharmacologic options available to the statin intolerant patient to manage their cardiovascular health in a primary care setting.
Three complex lipid cases will be presented in this activity. The cases will address risk assessment for cardiovascular disease and treatment options. The first case will be complicated by muscle side effects of the statin medication, leading to a discussion of statin dosing options. The second case will present with a mixed hyperlipidemia and discuss the use of combination therapy and the side effects that can occur due to drug–drug interactions. The third case will present with markedly high triglycerides, and dietary management will be discussed.
Learn the best practices to screen for and manage hypercholesterolemia and other lipid disorders in your clinic. Get updates on the latest drugs available to combat these conditions, and become familiar with the current practice guidelines for statin use in patients.
Advances in screening patients for cardiovascular risk using risk calculators, biomarkers and other tests have the potential to transform the field of preventive cardiovascular medicine. Dr. James de Lemos reviews the latest evidence on the use of screening to risk stratify patients and predict which patients could most benefit from early interventions.